Development Neuren Pharmaceuticals (NEU-ASX) | Speculative Buy | Valuation: AUD7.70This is a key result in line with our research thesis.Trofinetide (formerly NNZ-2566) is Neuren’s primary asset and has been exclusively licensed to Acadia Pharmaceuticals (NASDAQ:ACAD) for North America. Today Acadia announced a robustly positive Phase 3 clinical trial outcome.This result derisks NEU and adds ~40% to our valuation at initiation.
- Forums
- ASX - By Stock
- report
Development Neuren Pharmaceuticals (NEU-ASX) | Speculative Buy |...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.21 |
Change
-0.270(1.74%) |
Mkt cap ! $1.940B |
Open | High | Low | Value | Volume |
$15.20 | $15.33 | $15.02 | $2.486M | 163.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 254 | $15.21 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.22 | 819 | 18 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
14 | 312 | 15.210 |
11 | 678 | 15.200 |
9 | 746 | 15.190 |
7 | 505 | 15.180 |
8 | 676 | 15.170 |
Price($) | Vol. | No. |
---|---|---|
15.230 | 1760 | 14 |
15.240 | 637 | 6 |
15.250 | 948 | 8 |
15.260 | 663 | 6 |
15.270 | 1126 | 7 |
Last trade - 11.31am 22/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |